Elanco Animal Health Stock (NYSE:ELAN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$23.67

52W Range

$8.02 - $27.72

50D Avg

$24.42

200D Avg

$19.80

Market Cap

$11.66B

Avg Vol (3M)

$4.82M

Beta

1.89

Div Yield

-

ELAN Company Profile


Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

9,000

IPO Date

Sep 20, 2018

Website

ELAN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 22
Farm Animal$2.36B$2.25B$2.22B
Swine$379.00M$366.00M$384.00M
Pet Health$2.30B$2.14B$2.14B
Contract Manufacturing$53.00M$46.00M$54.00M
Cattle$1.13B$1.01B$944.00M
Poultry$858.00M$796.00M$716.00M

Fiscal year ends in Dec 25 | Currency in USD

ELAN Financial Summary


Dec 25Dec 24Dec 23
Revenue$4.71B$4.44B$4.42B
Operating Income$795.00M$251.00M$326.00M
Net Income$-232.00M$338.00M$-1.23B
EBITDA$795.00M$1.49B$-224.00M
Basic EPS$-0.47$0.68$-2.50
Diluted EPS$-0.47$0.68$-2.50

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Feb 24, 26 | 8:00 AM
Q3 25Nov 05, 25 | 8:00 AM
Q2 25Aug 07, 25 | 9:00 AM

Peer Comparison


TickerCompany
EHCEncompass Health Corporation
RVMDRevolution Medicines, Inc.
NBIXNeurocrine Biosciences, Inc.
VTRSViatris Inc.
QGENQiagen N.V.
RVTYRevvity, Inc.
ALGNAlign Technology, Inc.
RDYDr. Reddy's Laboratories Limited
SOLVSolventum Corporation
ENSGThe Ensign Group, Inc.